Renal cell carcinoma (RCC) is one of the most aggressive urological tumors worldwide. Despite significant advances in molecular characterization and therapy, the disease remains clinically challenging due to late diagnosis, complex pathomechanisms and a high rate of treatment resistance. New insights into genetics, metabolism, immune interaction and tumor microenvironment have not only deepened our understanding of the pathophysiology, but have also paved the way for innovative, personalized therapies.
Autoren
- Tanja Schliebe
Publikation
- Nephrologie-Special
Related Topics
You May Also Like
- "Survey of Health, Ageing and Retirement in Europe" (SHARE)
Analysis of polypharmacy in ≥65-year-olds
- New perspectives for clinics and research
Ageing, cellular senescence and Parkinson’s disease
- From early intervention to individualization
The new guidelines at a glance
- Artificial intelligence
Dr. ChatGPT: Large language models in everyday clinical practice
- COPD therapy
Drug therapy – Update 2025
- Focus on prevention
Colorectal cancer screening – an update
- From symptom to diagnosis
Oncology – Thymoma
- Shared decision making